Back to top
more

Abbott Laboratories (ABT)

(Real Time Quote from BATS)

$116.48 USD

116.48
1,818,379

-1.25 (-1.06%)

Updated Nov 6, 2024 11:48 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 251)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Abbott (ABT) Hits a 52-Week High: What's Driving the Stock?

by Zacks Equity Research

The market is upbeat about Abbott's (ABT) recent FDA approvals and buyouts.

    Abbott to Gain from Alere's Takeover Due for Oct 3 Closure

    by Zacks Equity Research

    Alere's acquisition would help Abbott (ABT) explore new channels and geographies, including forays into fast growing outlets like doctors' offices, clinics, pharmacies and at-home testing.

      Abbott Gets FDA Nod for FreeStyle Libre, Boosts Diabetes Arm

      by Zacks Equity Research

      Abbott's (ABT) diabetes care segment to strengthen with the FDA approval for FreeStyle Libre Flash glucose monitoring system.

        Abbott's Ellipse ICD Receives FDA Approval for MRI Scans

        by Zacks Equity Research

        Abbott's (ABT) Rhythm Management segment to gain traction with the latest FDA approval of Ellipse ICD for MR-conditioning labeling.

          Boston Scientific's Resonate Devices Boost Cardiac Rhythm Arm

          by Zacks Equity Research

          Boston Scientific (BSX) is consistently strengthening its Cardiac Rhythm Management segment.

            Medtronic (MDT) Initiates Study on CoreValve Evolut PRO TAVI

            by Zacks Equity Research

            Medtronic (MDT) to initiate FORWARD PRO Clinical Study for evaluating the safety standards of self-expanding TAVI system over longer-term.

              Abiomed's Latest Regulatory Progress Boosts Impella Line

              by Zacks Equity Research

              We believe that robust demand for Impella products will continue to drive Abiomed's (ABMD) top line over the long term.

                Here's Why You Should Add Abbott (ABT) to Your Portfolio Now

                by Zacks Equity Research

                The market is upbeat about Abbott (ABT) acquiring the national reimbursement for FreeStyleLibre glucose monitoring system in the United Kingdom. Several product launches also add value.

                  Abbott's (ABT) FreeStyle Libre Gets UK Reimbursement Nod

                  by Zacks Equity Research

                  Abbott's (ABT) diabetes care segment to further strengthen with the FreeStyle Libre glucose monitoring system's latest U.K. national reimbursement grant.

                    4 Top MedTech Stocks for Dividend Investors in 2017

                    by Zacks Equity Research

                    Dividend stocks are always investors' preferred choice as they provide steady income and cushion against market risks.

                      Abbott (ABT) Hits a 52-Week High: What's Driving the Stock?

                      by Zacks Equity Research

                      Abbott's (ABT) recent FDA approval for Full MagLev HeartMate 3 Left Ventricular Assist Device has boosted investor confidence.

                        Forget Abbott, Buy These 4 High-Growth MedTech Stocks Instead

                        by Zacks Equity Research

                        The share price performance of Abbott Laboratories (ABT) has been disappointing over the last three years. Of the prime issues plaguing Abbott, foreign exchange is a major one.

                          Abbott's (ABT) FreeStyle Libre Gets Japan Reimbursement Nod

                          by Zacks Equity Research

                          Abbott's (ABT) diabetes care segment to further strengthen with the FreeStyle Libre glucose monitoring system's latest Japanese national reimbursement grant.

                            Abbott's AMPLATZER Pivotal Study to Strengthen Vascular Arm

                            by Zacks Equity Research

                            Abbott (ABT) is consistently trying to expand its vascular business. It has initiated the clinical study of AMPLATZER device to correct common congenital heart defect in newborns.

                              Abbott's (ABT) FDA Nod for LVAD Boosts Medical Devices Arm

                              by Zacks Equity Research

                              Abbott Laboratories' (ABT) receipt of FDA approval for its Full MagLev HeartMate 3 LVAD strengthens one of its major business segments.

                                Agilent (A) Sues Former Employees for Infringing IP Rights

                                by Zacks Equity Research

                                Agilent Technologies has sued its former employees who formed Shanghai Echrom Electronic Technology Co.

                                  Why Is Abbott Laboratories (ABT) Down 3.1% Since the Last Earnings Report?

                                  by Zacks Equity Research

                                  Abbott Laboratories (ABT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                    Abbott-North West London Pathology Expand in Diagnostics

                                    by Zacks Equity Research

                                    Abbott Laboratories' (ABT) collaboration with North West London Pathology to strengthen its steadily growing diagnostics arm.

                                      The Zacks Analyst Blog Highlights: Oracle, Pfizer, Abbott, Alphabet and Schlumberger

                                      by Zacks Equity Research

                                      The Zacks Analyst Blog Highlights: Oracle, Pfizer, Abbott, Alphabet and Schlumberger

                                        Swarup Gupta headshot

                                        Profit from the Dollar's Dip with These 5 S&P 500 Stocks

                                        by Swarup Gupta

                                        Companies with significant overseas exposure stand to gain from the dollar's dip.

                                          Company News for July 21, 2017

                                          by Zacks Equity Research

                                          Companies In The News are: ABT,KMI,PM,TRV

                                            Abbott Labs (ABT) Beats on Q2 Earnings and Sales, View Up

                                            by Zacks Equity Research

                                            Abbott Labs' (ABT) Q2 performance was strong on solid EPD and Medical Device growth. The stock's guidance for 2017 has also been raised.

                                              Abbott (ABT) Tops Earnings Estimates in Q2, Misses on Sales

                                              by Zacks Equity Research

                                              Abbott Laboratories (ABT) gains on strong Q2 performance. Raised guidance buoys optimism.

                                                Tracey Ryniec headshot

                                                The Hottest Earnings Charts of the Week

                                                by Tracey Ryniec

                                                It's not easy to beat on earnings nearly every quarter but these 5 companies are doing it.

                                                  Medical Product Stocks' Earnings on Jul 20: ABT, ISRG & More

                                                  by Zacks Equity Research

                                                  The market remained jittery towards medical space due to uncertainties surrounding the future of the healthcare act.